Laboratorios Farmaceuticos Rovi, S.A. (LABFF)
USD 90.61
(0.0%)
USD 90.61
(0.0%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 492.28 Million EUR | -5.26% |
| 2022 | 519.61 Million EUR | 35.03% |
| 2021 | 384.82 Million EUR | 59.47% |
| 2020 | 241.3 Million EUR | 12.39% |
| 2019 | 214.7 Million EUR | 22.98% |
| 2018 | 174.59 Million EUR | 4.22% |
| 2017 | 167.51 Million EUR | 9.38% |
| 2016 | 153.14 Million EUR | 2.83% |
| 2015 | 148.93 Million EUR | 3.81% |
| 2014 | 143.46 Million EUR | 8.12% |
| 2013 | 132.69 Million EUR | 4.97% |
| 2012 | 126.41 Million EUR | 9.67% |
| 2011 | 115.26 Million EUR | 20.29% |
| 2010 | 95.82 Million EUR | 47.8% |
| 2009 | 64.83 Million EUR | -25.72% |
| 2008 | 87.28 Million EUR | 28.78% |
| 2007 | 67.78 Million EUR | 28.77% |
| 2006 | 52.63 Million EUR | -100.0% |
| 2005 | 7846.54 Billion EUR | 1328835.9% |
| 2004 | -590.52 Million EUR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 110.31 Million EUR | 28.77% |
| 2024 Q1 | 85.67 Million EUR | -38.17% |
| 2023 Q4 | 138.56 Million EUR | 1.69% |
| 2023 Q2 | 91.44 Million EUR | -27.44% |
| 2023 FY | 492.28 Million EUR | -5.26% |
| 2023 Q3 | 136.25 Million EUR | 49.01% |
| 2023 Q1 | 126.02 Million EUR | -28.6% |
| 2022 Q4 | 176.51 Million EUR | 51.14% |
| 2022 Q1 | 124.68 Million EUR | 4.73% |
| 2022 FY | 519.61 Million EUR | 35.03% |
| 2022 Q3 | 116.78 Million EUR | 14.92% |
| 2022 Q2 | 101.62 Million EUR | -18.49% |
| 2021 Q4 | 119.05 Million EUR | 6.28% |
| 2021 Q1 | 69.79 Million EUR | 4.57% |
| 2021 Q2 | 83.95 Million EUR | 20.28% |
| 2021 Q3 | 112.01 Million EUR | 33.43% |
| 2021 FY | 384.82 Million EUR | 59.47% |
| 2020 FY | 241.3 Million EUR | 12.39% |
| 2020 Q1 | 54.91 Million EUR | -6.09% |
| 2020 Q4 | 66.74 Million EUR | 6.22% |
| 2020 Q2 | 56.8 Million EUR | 3.45% |
| 2020 Q3 | 62.83 Million EUR | 10.61% |
| 2019 Q1 | 46.57 Million EUR | 3.5% |
| 2019 Q2 | 54.9 Million EUR | 17.87% |
| 2019 FY | 214.7 Million EUR | 22.98% |
| 2019 Q4 | 58.47 Million EUR | 6.81% |
| 2019 Q3 | 54.75 Million EUR | -0.28% |
| 2018 Q4 | 45 Million EUR | -0.5% |
| 2018 FY | 174.59 Million EUR | 4.22% |
| 2018 Q3 | 45.22 Million EUR | 10.8% |
| 2018 Q2 | 40.81 Million EUR | -6.28% |
| 2018 Q1 | 43.55 Million EUR | -5.97% |
| 2017 Q2 | 42.32 Million EUR | 2.76% |
| 2017 Q1 | 41.19 Million EUR | -1.12% |
| 2017 FY | 167.51 Million EUR | 9.38% |
| 2017 Q4 | 46.31 Million EUR | 22.92% |
| 2017 Q3 | 37.68 Million EUR | -10.98% |
| 2016 Q3 | 35.65 Million EUR | -10.27% |
| 2016 Q2 | 39.73 Million EUR | 10.1% |
| 2016 FY | 153.14 Million EUR | 2.83% |
| 2016 Q4 | 41.65 Million EUR | 16.84% |
| 2016 Q1 | 36.09 Million EUR | -10.08% |
| 2015 Q3 | 35.34 Million EUR | -7.15% |
| 2015 Q1 | 35.39 Million EUR | -11.46% |
| 2015 FY | 148.93 Million EUR | 3.81% |
| 2015 Q4 | 40.13 Million EUR | 13.57% |
| 2015 Q2 | 38.06 Million EUR | 7.52% |
| 2014 Q1 | 34.14 Million EUR | 2.09% |
| 2014 FY | 143.46 Million EUR | 8.12% |
| 2014 Q3 | 33.46 Million EUR | -6.76% |
| 2014 Q4 | 39.97 Million EUR | 19.48% |
| 2014 Q2 | 35.88 Million EUR | 5.11% |
| 2013 Q2 | 36.49 Million EUR | 19.27% |
| 2013 Q3 | 32.16 Million EUR | -11.87% |
| 2013 Q4 | 33.44 Million EUR | 4.0% |
| 2013 FY | 132.69 Million EUR | 4.97% |
| 2013 Q1 | 30.59 Million EUR | -50.39% |
| 2012 Q2 | 33.78 Million EUR | 9.18% |
| 2012 FY | 126.41 Million EUR | 9.67% |
| 2012 Q3 | 31.02 Million EUR | -8.17% |
| 2012 Q4 | 61.67 Million EUR | 98.77% |
| 2012 Q1 | 30.94 Million EUR | -44.37% |
| 2011 Q2 | 31.9 Million EUR | 15.01% |
| 2011 Q3 | 27.81 Million EUR | -12.8% |
| 2011 FY | 115.26 Million EUR | 20.29% |
| 2011 Q4 | 55.63 Million EUR | 100.0% |
| 2011 Q1 | 27.73 Million EUR | 8.11% |
| 2010 Q4 | 25.65 Million EUR | 5.48% |
| 2010 Q1 | 22.13 Million EUR | 0.0% |
| 2010 Q2 | 23.71 Million EUR | 7.15% |
| 2010 FY | 95.82 Million EUR | 47.8% |
| 2010 Q3 | 24.32 Million EUR | 2.57% |
| 2009 FY | 64.83 Million EUR | -25.72% |
| 2008 FY | 87.28 Million EUR | 28.78% |
| 2007 FY | 67.78 Million EUR | 28.77% |
| 2006 FY | 52.63 Million EUR | -100.0% |
| 2005 FY | 7846.54 Billion EUR | 1328835.9% |
| 2004 FY | -590.52 Million EUR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Capstone Therapeutics Corp. | 9.61 Million USD | -5022.1% |
| Skye Bioscience, Inc. | -124.25 Thousand USD | 396302.043% |
| Santhera Pharmaceuticals Holding AG | 119.1 Million USD | -313.311% |
| Nascent Biotech, Inc. | -319.5 Thousand USD | 154176.437% |
| Qrons Inc. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| BioStem Technologies, Inc. | 15.42 Million USD | -3091.507% |
| CSL Limited | 7.56 Billion USD | 93.489% |
| Evofem Biosciences, Inc. | 11.7 Million USD | -4105.407% |
| Arch Therapeutics, Inc. | -2439.00 USD | 20183986.839% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | -278720.231% |
| Northwest Biotherapeutics, Inc. | -25.79 Million USD | 2008.229% |
| ProtoKinetix, Incorporated | -48.25 Thousand USD | 1020189.517% |
| Rebus Holdings, Inc. | - USD | -Infinity% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | - USD | -Infinity% |
| Acro Biomedical Co., Ltd. | 140.5 Thousand USD | -350280.783% |
| Eiger BioPharmaceuticals, Inc. | 14.99 Million USD | -3182.119% |
| Nanobac Pharmaceuticals, Incorporated | 3102.00 USD | -15869822.631% |
| Institute of Biomedical Research Corp. | - USD | -Infinity% |
| SQZ Biotechnologies Company | 9.79 Million USD | -4926.394% |
| Intellipharmaceutics International Inc. | 65.72 Thousand USD | -748873.04% |
| Propanc Biopharma, Inc. | -34.15 Thousand USD | 1441637.335% |
| Mesoblast Limited | -35.16 Million USD | 1499.809% |
| Marizyme, Inc. | 457.7 Thousand USD | -107455.79% |
| Genus plc | 178.7 Million USD | -175.481% |
| VioQuest Pharmaceuticals, Inc. | - USD | -Infinity% |
| Pharming Group N.V. | 220.1 Million USD | -123.66% |
| Therapeutic Solutions International, Inc. | 62.22 Thousand USD | -791024.289% |
| CNBX Pharmaceuticals Inc. | 410.16 Thousand USD | -119921.211% |
| Nymox Pharmaceutical Corporation | -11 Thousand USD | 4475418.182% |
| ContraFect Corporation | -154 Thousand USD | 319765.584% |
| PsyBio Therapeutics Corp. | -50 Thousand USD | 984670.0% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 76.76 Thousand USD | -641221.765% |
| IMV Inc. | -962.29 Thousand USD | 51257.23% |
| AXIM Biotechnologies, Inc. | -387.5 Thousand USD | 127140.962% |
| MultiCell Technologies, Inc. | 49.32 USD | -998144668.856% |
| ONE Bio Corp. | 20.12 Million USD | -2346.083% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 40.26 Million USD | -1122.613% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 48.9 Thousand USD | -1006617.791% |
| Q BioMed Inc. | -8988.00 USD | 5477236.182% |
| Emmaus Life Sciences, Inc. | 28.25 Million USD | -1642.293% |
| Mosaic ImmunoEngineering Inc. | - USD | -Infinity% |
| Biomind Labs Inc. | -15.42 Thousand USD | 3191781.795% |
| American Oriental Bioengineering, Inc. | 44.35 Million USD | -1009.804% |
| Provectus Biopharmaceuticals, Inc. | -1.14 Million USD | 43223.43% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 70 Thousand USD | -703164.286% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | -4952.00 USD | 9941234.895% |
| Curative Biotechnology, Inc. | -97.51 Thousand USD | 504930.026% |
| GB Sciences, Inc. | -624.00 USD | 78891926.923% |
| Alpha Cognition Inc. | -86.02 Thousand USD | 572338.109% |
| HST Global, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | - USD | -Infinity% |
| Halberd Corporation | -208.00 USD | 236675580.769% |
| Enzolytics Inc. | 30.7 Thousand USD | -1603016.452% |
| Agentix Corp. | - USD | -Infinity% |
| Resverlogix Corp. | - USD | -Infinity% |
| Nuo Therapeutics, Inc. | 482.43 Thousand USD | -101942.149% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.1 Billion USD | 55.589% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Endonovo Therapeutics, Inc. | -514.51 Thousand USD | 95780.356% |
| RespireRx Pharmaceuticals Inc. | - USD | -Infinity% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | 617.38 Thousand USD | -79637.246% |
| Zenith Capital Corp. | - USD | -Infinity% |
| Genscript Biotech Corporation | 409.55 Million USD | -20.201% |
| Ember Therapeutics, Inc. | - USD | -Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | -8856.00 USD | 5558873.713% |
| WPD Pharmaceuticals Inc. | - USD | -Infinity% |
| Cotinga Pharmaceuticals Inc. | -83.84 Thousand USD | 587208.97% |
| Kadimastem Ltd | -630.13 Thousand USD | 78223.363% |
| Helix BioMedix, Inc. | 987.98 Thousand USD | -49727.375% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | - USD | -Infinity% |
| LadRx Corporation | -11.83 Thousand USD | 4159669.075% |
| Cell Source, Inc. | - USD | -Infinity% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | -278720.231% |
| NovAccess Global Inc. | - USD | -Infinity% |
| Affymax, Inc. | 1.35 Million USD | -36173.628% |
| Itoco Inc. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | - USD | -Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | - USD | -Infinity% |
| CytoDyn Inc. | -29 Thousand USD | 1697634.483% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 450.04 Thousand USD | -109286.214% |
| SYBLEU INC | 11.69 Thousand USD | -4208903.078% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | - USD | -Infinity% |
| International Stem Cell Corporation | 4.6 Million USD | -10583.268% |
| Bioxytran, Inc. | -8285.00 USD | 5941982.921% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | - USD | -Infinity% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | - USD | -Infinity% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | - USD | -Infinity% |
| Innovation Pharmaceuticals Inc. | -373 Thousand USD | 132079.893% |
| Neutra Corp. | 14.33 Thousand USD | -3434047.192% |
| Windtree Therapeutics, Inc. | -82 Thousand USD | 600447.561% |
| PureTech Health plc | -1.6 Million USD | 30810.231% |
| Coeptis Therapeutics, Inc. | -1 Million USD | 49267.729% |
| IXICO plc | 3.27 Million USD | -14954.587% |
| IntelGenx Technologies Corp. | -694 Thousand USD | 71034.438% |
| Gelesis Holdings, Inc. | -1.79 Million USD | 27586.6% |
| CSL Limited | 7.7 Billion USD | 93.611% |
| Cellectis S.A. | 18 Thousand USD | -2734816.667% |